Relmada Therapeutics Inc. (RLMD)

[Biobonic]

How today's top line results reflect on RLMD and other thoughts

First a bit about SAGE, their drug is NOT an N-methyl-D-aspartate (NMDA) receptor antagonist.

In the top line results for SAGE, by day 42 of the trial 14% drop out in the arm which received the 30 mg dose. By day 42 of the trial 9% drop out in the arm which received the 20mg dose.

These people knew they were receiving the actual trial drug, not the placebo...yet to have 23% drop out before the end of the first segment then another 9% not bother to take the drug on the extended segment of the trial. Doesn't speak well of the drug, imo.

Onto AXSM, the combo of bupropion and DM does produce a slow acting N-methyl-D-aspartate (NMDA) receptor antagonist,

As Relmada's REL-1017 is the same type drug, the positive results of the AXSM trial should be replicated by REL-1017.


And as to patents, I did find this in the latest annual for AXSM:

In 2012, we entered into three exclusive license agreements with Antecip Bioventures II LLC, or Antecip, an entity owned by our Chief Executive Officer and Chairman of the Board, Herriot Tabuteau, M.D., in which we were granted exclusive licenses to develop, manufacture, and commercialize Antecip’s patents and applications related to the development of AXS-05 and AXS-02...

page 34

There are a number of patents on the AXS-05

As of March 11, 2019, our intellectual property portfolio contains 192 issued patents and more than 165 pending applications in the United States and worldwide. Thirty-one issued United States patents and three issued foreign patents covering our AXS-05 product candidate have claims covering pharmaceutical composition, drug delivery, and pharmacokinetics with protection extending through 2034 for our issued and pending applications.

There is opportunity for all...but I'm a Relmada exclusive.